Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janssen Sporanox

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Itraconazole injection and oral solution gains new indication May 9 for empiric therapy in febrile neutropenic patients with suspected fungal infections. FDA issued a public health advisory May 9 advising of hepatotoxicity associated with Sporanox capsules and Novartis' Lamisil (terbinafine) tablets and of "a small but real risk of developing congestive heart failure" with Sporanox. Labeling for both products was revised to strengthen the discussion on hepatotoxicity. A revised boxed warning for Sporanox warns against use of the product in patients with cardiac dysfunction and adds contraindications against administration with dofetilide (Pfizer's antiarrythmic Tikosyn) and pimozide (Gate's antipsychotic Orap)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS001510

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel